Synthesis, structure, reactivity and enzyme inhibitory activity of the new cationic ruthenium complexes [Ru(κ3‐L)(EPh3)2Cl]BF4 [L = 2,4,6‐tris(2‐pyridyl)‐1,3,5‐triazine (tptz); E = P (1), As (2)] and their substitution products [Ru(κ3‐tptz)(PPh3)(dtc)]Cl (3), [Ru(κ3‐tptz)(PPh3)(CN)2] (4), [Ru(κ3‐tptz)(AsPh3)(dtc)]BF4 (5), and [Ru(κ3‐tptz)(AsPh3)(CN)2] (6) are reported. The complexes were characterized by analytical and spectroscopic methods and the structures of the complexes 1, 2 and 3 determined by X‐ray diffraction studies. C−H···X (X = Cl, F and S), C−H···π and π−π interactions were observed in these complexes. Further studies indicated that the complexes [Ru(κ3‐L)(EPh3)2Cl]+ could find application as precursors in the synthesis of other ruthenium complexes or as metallo‐ligands. The complexes also interact with DNA, which was illustrated by absorption titration studies with CT‐DNA and inhibition of topoisomerase II of the filarial parasite Setaria cervi. (© Wiley‐VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004)
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: